Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety

for
Cancer, Survivorship, Anxiety
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT07305740

Recruiting

Hypersight and Ethos In Pediatric Radiotherapy

for
Cancer
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 0 - 18

Code: NCT07528547

Recruiting

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

for
Solid Tumors (Phase 1)
Location: New Haven CT, Springdale AR, Houston TX
Sponsor: Adcendo ApS

Sex: All

Age: 18+

Code: NCT07362888

Phase 1, Recruiting

A Pilot Randomized Controlled Trial of a Social Network Intervention

for
Advanced Cancer, Older Adults (65 Years and Older),
Location: Rochester NY
Sponsor: University of Rochester

Sex: All

Age: 65+

Code: NCT07393529

Recruiting

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

for
Solid Tumors
Location: New York NY, Virginia Beach VA, Bethesda MD,
Sponsor: DualityBio Inc.

Sex: All

Age: 18+

Code: NCT06953089

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

for
Solid Tumor
Location: Providence RI, Philadelphia PA, Fairfax VA,
Sponsor: Chugai Pharmaceutical

Sex: All

Age: 18+

Code: NCT05907980

Phase 1, Recruiting

OCT Vibrography for Biomechanical Properties of Tissues

for
Cornea, Skin Diseases, Gingival Diseases
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18 - 70+

Code: NCT05759780

Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

for
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors,
Location: Lake Success NY, New York NY, Morristown NJ, Tamarac FL,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18+

Code: NCT07262619

Phase 1, Phase 2, Recruiting

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Houston TX, San Antonio TX, La Jolla CA
Sponsor: OBI Pharma, Inc

Sex: All

Age: 18+

Code: NCT07124117

Phase 1, Phase 2, Recruiting

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: San Antonio TX
Sponsor: TiumBio Co., Ltd.

Sex: All

Age: 18+

Code: NCT05204862

Phase 1, Phase 2, Recruiting

Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

for
Skin Lesion
Location: Irvine CA
Sponsor: University of California, Irvine

Sex: All

Age: 0+

Code: NCT01771718

Recruiting

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

for
Breast Cancer
Location: Boston MA, Wellesley Hills MA, New York NY, Sewell NJ,
Sponsor: American College of Radiology

Sex: Female

Age: 45 - 70+

Code: NCT05625659

Recruiting

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma,
Location: Toronto, Dallas TX, San Antonio TX
Sponsor: Auricula Biosciences Inc.

Sex: All

Age: 18+

Code: NCT07148128

Phase 1, Phase 2, Recruiting

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

for
Neoplasms
Location: Toronto, Montreal, Philadelphia PA, San Antonio TX
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT07438782

Phase 1, Recruiting

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

for
Solid Malignancies
Location: Miami FL, Dothan AL, Houston TX, Palo Alto CA
Sponsor: Immunome, Inc.

Sex: All

Age: 18+

Code: NCT07505771

Phase 1, Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

for
Neoplasms
Location: New Haven CT, Toronto, Sarasota FL, Houston TX,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06884618

Phase 1, Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

for
Breast Cancer
Location: Westbury NY, New York NY, Midlothian VA, Plantation FL,
Sponsor: Celcuity Inc

Sex: All

Age: 18+

Code: NCT06757634

Phase 3, Recruiting

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06651593

Phase 2, Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for
Breast Neoplasms
Location: Sherbrooke, Montreal, Saint-Charles-Borromee, Ottawa,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06926868

Phase 2, Phase 3, Recruiting

Re-Engaging AYA Survivors in Cancer-Related Healthcare

for
Cancer
Location: Philadelphia PA, Columbus OH
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 15 - 29

Code: NCT07138040

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial